LFCM
AKRO

Long Focus Capital Management’s Akero Therapeutics AKRO Stock Holding History

Long Focus Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-720,000
Closed -$34.2M – 94
2025
Q3 		$34.2M Hold
720,000
– – 1.13% 26
2025
Q2 		$38.4M Sell
720,000
-9,504
-1% -$432K 1.45% 15
2025
Q1 		$29.5M Buy
729,504
+9,900
+1% +$420K 0.99% 26
2024
Q4 		$20M Hold
719,604
– – 0.65% 31
2024
Q3 		$20.6M Hold
719,604
– – 0.72% 26
2024
Q2 		$16.9M Buy
719,604
+391,000
+119% +$8.36M 0.65% 29
2024
Q1 		$8.3M Sell
328,604
-181,396
-36% -$4.36M 0.42% 50
2023
Q4 		$11.9M Buy
510,000
+366,000
+254% +$7.22M 0.4% 32
2023
Q3 		$7.28M Hold
144,000
– – 0.26% 46
2023
Q2 		$6.72M Sell
144,000
-20,000
-12% -$917K 0.31% 48
2023
Q1 		$6.27M Hold
164,000
– – 0.36% 46
2022
Q4 		$8.99M Sell
164,000
-128,000
-44% -$5.48M 0.62% 34
2022
Q3 		$9.94M Buy
292,000
+2,000
+0.7% +$30.6K 0.97% 16
2022
Q2 		$2.74M Buy
+290,000
New +$3.02M 0.29% 55

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Long Focus Capital Management's AKRO Position: Q4 2025 in Review

Long Focus Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 720,000 shares — an estimated $34.2M sold.

Long Focus Capital Management first reported a position in AKRO in Q2 2022 and held it in 14 quarters. The position peaked at $38.4M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Long Focus Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Long Focus Capital Management sold 720,000 Akero Therapeutics shares in Q4 2025, an estimated $34.2M.
  • Long Focus Capital Management first reported a position in Akero Therapeutics in Q2 2022 and held it in 14 quarters.
  • Long Focus Capital Management's Akero Therapeutics position peaked at $38.4M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Long Focus Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.